Expertise in
39
conditions

Dr. Michael Bukhalo

Dermatology
Office
5301 Keystone Ct, 
Rolling Meadows, IL 
Offers Telehealth
Expertise in
39
conditions
Office
5301 Keystone Ct, 
Rolling Meadows, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Bukhalo is a Dermatologist in Rolling Meadows, Illinois. Dr. Bukhalo is highly rated in 39 conditions, according to our data. His top areas of expertise are Plaque Psoriasis, Actinic Keratosis, Psoriasis, and Neurocutaneous Melanosis.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in IL
Hospital Affiliations
Northwest Community Hospital 1
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
Nippon Life
  • INSURANCE PLAN
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 22 Less Insurance Carriers -

Locations

Office
5301 Keystone Ct, Rolling Meadows, IL 60008
Call: 847-392-5440

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
Enrollment Status: Terminated
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Enrollment Status: Completed
Publish Date: September 25, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: August 18, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Enrollment Status: Withdrawn
Publish Date: November 07, 2017
Intervention Type: Drug, Device
Study Phase: Phase 3
View 12 Less Clinical Trials

23 Total Publications

Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study.
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study.
Journal: Journal of the American Academy of Dermatology
Published: June 27, 2025
View All 23 Publications
Similar Doctors
Expertise in
90
conditions
Dr. Kyle T. Amber
Dermatology
Expertise in
90
conditions
Dr. Kyle T. Amber
Dermatology

Rush University Medical Group

1725 W Harrison St, 
Chicago, IL 
 (21.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kyle Amber is a Dermatologist in Chicago, Illinois. Dr. Amber is highly rated in 90 conditions, according to our data. His top areas of expertise are Bullous Pemphigoid, Pemphigus, Pemphigus Vulgaris, and Bullae. Dr. Amber is currently accepting new patients.

Joan Guitart
Expertise in
16
conditions
Dr. Joan Guitart
Dermatology
Expertise in
16
conditions
Dr. Joan Guitart
Dermatology
676 N St Clair St Ste 1600, Arkes Pavilion, 
Chicago, IL 
 (23.3 miles away)
312-695-8106
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joan Guitart is a Dermatologist in Chicago, Illinois. Dr. Guitart has been practicing medicine for over 43 years is highly rated in 16 conditions, according to our data. His top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Lymphomatoid Papulosis.

Pedram Gerami
Expertise in
13
conditions
Dr. Pedram Gerami
Dermatology
Expertise in
13
conditions
Dr. Pedram Gerami
Dermatology
676 N St Clair St Ste 1600, Arkes Pavilion, 
Chicago, IL 
 (23.3 miles away)
312-695-8106
Experience:
25+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Pedram Gerami is a Dermatologist in Chicago, Illinois. Dr. Gerami has been practicing medicine for over 25 years is highly rated in 13 conditions, according to our data. His top areas of expertise are Melanoma, Familial Atypical Multiple Mole Melanoma Syndrome, Tieche-Jadassohn Nevus, and Giant Congenital Melanocytic Nevus.

VIEW MORE Dermatologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bukhalo's expertise for a condition
ConditionClose
    • Distinguished
    • Actinic Keratosis
      Dr. Bukhalo is
      Distinguished
      . Learn about Actinic Keratosis.
      See more Actinic Keratosis experts
    • Bowen's Disease
      Dr. Bukhalo is
      Distinguished
      . Learn about Bowen's Disease.
      See more Bowen's Disease experts
    • Familial Atypical Multiple Mole Melanoma Syndrome
      Dr. Bukhalo is
      Distinguished
      . Learn about Familial Atypical Multiple Mole Melanoma Syndrome.
      See more Familial Atypical Multiple Mole Melanoma Syndrome experts
    • Giant Congenital Melanocytic Nevus
      Dr. Bukhalo is
      Distinguished
      . Learn about Giant Congenital Melanocytic Nevus.
      See more Giant Congenital Melanocytic Nevus experts
    • Giant Congenital Nevus
      Dr. Bukhalo is
      Distinguished
      . Learn about Giant Congenital Nevus.
      See more Giant Congenital Nevus experts
    • Neurocutaneous Melanosis
      Dr. Bukhalo is
      Distinguished
      . Learn about Neurocutaneous Melanosis.
      See more Neurocutaneous Melanosis experts
    View All 10 Distinguished Conditions
    • Advanced
    • Basal Cell Skin Cancer
      Dr. Bukhalo is
      Advanced
      . Learn about Basal Cell Skin Cancer.
      See more Basal Cell Skin Cancer experts
    • Cerebral Cavernous Malformation
      Dr. Bukhalo is
      Advanced
      . Learn about Cerebral Cavernous Malformation.
      See more Cerebral Cavernous Malformation experts
    • Cherry Angioma
      Dr. Bukhalo is
      Advanced
      . Learn about Cherry Angioma.
      See more Cherry Angioma experts
    • Comedones
      Dr. Bukhalo is
      Advanced
      . Learn about Comedones.
      See more Comedones experts
    • Contact Dermatitis
      Dr. Bukhalo is
      Advanced
      . Learn about Contact Dermatitis.
      See more Contact Dermatitis experts
    • Eosinophilic Pustular Folliculitis
      Dr. Bukhalo is
      Advanced
      . Learn about Eosinophilic Pustular Folliculitis.
      See more Eosinophilic Pustular Folliculitis experts
    View All 29 Advanced Conditions
    • Experienced
    • Acanthosis Nigricans
      Dr. Bukhalo is
      Experienced
      . Learn about Acanthosis Nigricans.
      See more Acanthosis Nigricans experts
    • Acne
      Dr. Bukhalo is
      Experienced
      . Learn about Acne.
      See more Acne experts
    • Acrogeria, Gottron Type
      Dr. Bukhalo is
      Experienced
      . Learn about Acrogeria, Gottron Type.
      See more Acrogeria, Gottron Type experts
    • Acrokeratoelastoidosis of Costa
      Dr. Bukhalo is
      Experienced
      . Learn about Acrokeratoelastoidosis of Costa.
      See more Acrokeratoelastoidosis of Costa experts
    • Alopecia Areata
      Dr. Bukhalo is
      Experienced
      . Learn about Alopecia Areata.
      See more Alopecia Areata experts
    • Atopic Dermatitis
      Dr. Bukhalo is
      Experienced
      . Learn about Atopic Dermatitis.
      See more Atopic Dermatitis experts
    View All 86 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    1. Homepage
    2. Dermatologists Rolling Meadows, IL
    3. Dr. Michael Bukhalo
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.